


Claims

What is claimed is:

1. A pharmaceutical composition comprising an isomerically pure form of a compound of Formula (I):



wherein the compound of Formula (I) is present in a therapeutically effective amount to preferentially potentiate an $\alpha 4\beta 3\delta$ GABA_A receptor as compared to an $\alpha 1\beta 2\gamma 2$ GABA_A receptor.

2. The composition of claim 1, wherein the compound of Formula (I) preferentially positively modulates an $\alpha 4\beta 3\delta$ GABA_A receptor as compared to an $\alpha 1\beta 2\gamma 2$ GABA_A receptor.
3. The composition of claim 2, wherein an EC₅₀ of the compound of Formula (I) for an $\alpha 4\beta 3\delta$ GABA_A receptor is less than 50% of an EC₅₀ of the compound of Formula (I) for an $\alpha 1\beta 2\gamma 2$ GABA_A receptor.
4. The composition of claim 3, wherein an EC₅₀ of the compound of Formula (I) for an $\alpha 4\beta 3\delta$ GABA_A receptor is less than 20% of an EC₅₀ of the compound of Formula (I) for an $\alpha 1\beta 2\gamma 2$ GABA_A receptor.
5. The composition of claim 1, wherein an EC₅₀ of the compound of Formula (I) for an $\alpha 4\beta 3\delta$ GABA_A receptor is less than 500 nM.

6. The composition of claim 1, wherein the composition is effective for treatment of a GABA_A disorder.
7. The composition of 6, wherein the GABA_A disorder is selected from the group consisting of acute pain, an addictive disorder, Alzheimer's disease, Angelman's syndrome, anti-social personality disorder, an anxiety disorder, attention deficit hyperactivity disorder (ADHD), an attention disorder, an auditory disorder, autism, an autism spectrum disorder, bipolar disorder, chronic pain, a cognitive disorder, a compulsive disorder, a convulsive disorder, dementia, depression, dysthymia, an epileptic disorder, essential tremor, epileptogenesis, fragile X syndrome, generalized anxiety disorder (GAD), Huntington's disease, injury related pain syndrome, insomnia, ischemia, Lewis body type dementia, a memory disorder, migraines, a mood disorder, movement disorder, a neurodegenerative disease, neuropathic pain, an obsessive compulsive disorder, pain, a panic disorder, Parkinson's disease, a personality disorder, posttraumatic stress disorder (PTSD), psychosis, Rett syndrome, a schizoaffective disorder, schizophrenia, a schizophrenia spectrum disorder, a seizure disorder, a sleep disorder, social anxiety disorder, status epilepticus, stress, stroke, tinnitus, traumatic brain injury (TBI), vascular disease, vascular malformation, vascular type dementia movement disorder, Wilson's disease, and withdrawal syndrome.
8. The composition of 7, wherein the GABA_A disorder is an epileptic disorder, epileptogenesis, or a seizure disorder.
9. The composition of claim 1, wherein the composition is formulated for oral administration.
10. The composition of claim 1, the composition is formulated as a single daily dosage.